Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New hope for rare leukemia: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 trial tests whether adding IMM01 (Timdarpacept) to standard azacitidine improves outcomes for people newly diagnosed with chronic myelomonocytic leukemia (CMML). About 170 participants will receive either the combination or a placebo plus azacitidine. The main goals …
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New injection aims to make heart plaque less dangerous
Disease control Recruiting nowThis early-phase trial tests an injectable drug called IMC-001 in 18 people who recently had a heart attack or unstable angina. The goal is to see if it can safely stabilize fatty plaque in the heart arteries, making it less likely to rupture. Participants receive either the drug…
Phase: EARLY_PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New drug IMC-003 put to the test in healthy women – no cure expected
Knowledge-focused Recruiting nowThis early-stage study tests the safety and tolerability of a new drug called IMC-003 in healthy postmenopausal women aged 45 to 75. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to…
Phase: PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC